Business Wire

Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors

Jaa

Kite, a Gilead Company (Nasdaq: GILD), today announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting human papillomavirus type 16 (HPV-16) E7 in solid tumor cancers caused by HPV. These findings were presented today in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract #3043).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180604005335/en/

TCR therapy is a type of personalized immunotherapy designed to activate the immune system's ability to recognize and target specific tumors. TCR therapy involves engineering an individual’s own T cells to express naturally occurring receptors that can recognize specific tumor antigens. Epithelial cancers caused by HPV, including cervical, head and neck, anal and genital cancers, contain a protein called E7 inside tumor cells. Patients with these tumors whose cancers have relapsed and/or are refractory to standard therapy are currently incurable.

In this study, eight patients with metastatic HPV-16 cancers received a single infusion of gene-engineered E7 T cells at one of three dose levels. Patients had received between three and seven prior lines of systemic cancer therapy. In the initial six patients, the E7 TCR was expressed by 90-99 percent of the infused T cells, and E7 T cells were detectable in the peripheral blood six weeks following treatment. The study is ongoing.

Partial responses (Response Evaluation Criteria in Solid Tumors (RECIST); RECIST 1.1) were observed in three out of the seven evaluable patients and another two patients had stable disease. To date, the responses have lasted as long as nine months and have occurred in patients with vulvar, oropharyngeal and anal cancer. Two of these patients had been previously treated with anti-PD1 checkpoint blockade.

“Metastatic HPV-cancers are incurable and poorly addressed by standard therapies,” said Christian S. Hinrichs, MD, Lasker Clinical Research Scholar at the Center for Cancer Research’s Experimental Transplantation and Immunology Branch (ETIB) at the NCI and lead study investigator. “The early results from this Phase 1 trial support the continued evaluation of TCR therapy in HPV-associated cancers.”

No dose-limiting toxicity occurred. The most common grade 3 or higher adverse events were anemia, lymphopenia, leukopenia and neutropenia, each of which occurred in all seven evaluable patients.

The trial is part of a Cooperative Research and Development Agreement (CRADA) between the ETIB of the NCI and Kite to further the research and clinical development of TCR product candidates for the treatment of HPV-associated cancers. Patients interested in enrolling in the 16-C-0154 clinical trial can call the National Cancer Institute’s toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615) or visit https://trials.cancer.gov.

HPV has a causal role in nearly all cervical cancers, and in many head and neck and anogenital malignancies. HPV-16 is the most commonly found strain in these cancers. More than 33,000 cases of HPV-associated cancers are diagnosed each year in the U.S. and more than 10,000 deaths are attributed to the disease, according to the Centers for Disease Control and Prevention. Current therapies for HPV-associated tumors have low response rates and poor response duration.

“Findings from this Phase 1 study validate the E7 protein as a viral target for TCR therapy,” said Alessandro Riva, MD, Gilead’s Executive Vice President, Oncology Therapeutics & Head, Cell Therapy. “We plan to submit an IND for our TCR candidate, KITE-439, for HPV-16 E7 solid tumors by the end of the year, and we continue to explore other potential TCR therapy candidates for a variety of cancers in partnership with the NCI.”

KITE-439 is investigational and has not been proven safe or efficacious.

About Kite

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from additional clinical trials involving KITE-439 for the treatment of HPV-16 E7 solid tumors or other HPV-associated cancers. In addition, Kite may be unable to submit the IND for KITE-439 in the currently anticipated timelines or at all. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.

For more information on Kite, please visit the company’s website at  www.kitepharma.com . Learn more about Gilead at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Nathan Kaiser, 650-522-1853

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Limelight Networks and Ericsson to Accelerate Content Delivery and Edge Cloud Adoption18.10.2018 18:00Tiedote

Limelight Networks (NASDAQ: LLNW) and Ericsson (NASDAQ: ERIC) have signed an agreement to collaborate on content delivery and edge cloud services. As more traffic shifts to the public internet from private networks, the need for high performance networks and distributed infrastructure is required to maintain a high-quality user experience. A key solution to this is edge cloud computing. Providing computing capabilities close to the user or device gives a superior quality of service. For new low latency applications such as IoT, gaming, and virtual reality, robust computing capabilities at the edge of the network are needed. Communications service providers and technology companies will play a pivotal role in scaling the next wave of internet traffic. Ericsson is partnering with service providers globally to build the Ericsson Unified Delivery Network (UDN) Edge Cloud Platform – a web-scale edge delivery network, driving performance benefits and cost efficiencies. Content delivery is th

World Leader in High-End Mobile Security, Kaymera Technologies, to Expand Adaptive Mobile Threat Defense Footprint18.10.2018 16:56Tiedote

Kaymera Technologies, the leader in high-end Mobile Threat Defense solutions, today announced that BGŻ BNP Paribas have chosen the Kaymera’s Adaptive Mobile Threat Defense Platform to help protect personal and business-related mobile data across its employee base and business partners. According to a recent reports survey of IT Security professionals on Bring Your Own Device (BYOD), one in five organizations has suffered a mobile security breach, primarily driven by malware and malicious WiFi. 24% of organizations confirmed their mobile devices have connected to malicious WiFi networks while 48% were unsure if there have been any mobile security incidents. With at least one device in every large organization likely infected with malware, and one-third of executives experiencing network attacks, most enterprises are looking for a strong defense system against mobile threats. “We were looking for solutions to further increase mobility across our organization by boosting our mobile securi

Piraeus Bank Signs Financing Agreement of €40 million with Thomas Cook Hotel Investments18.10.2018 16:18Tiedote

Piraeus Bank signed a financing agreement of €40 million with Thomas Cook Hotel Investments (TCHI), a joint venture between Thomas Cook plc and LMEY Investments AG. Piraeus Bank is the sole financial partner of TCHI in Greece and the financing will be used to invest in local hotel properties. Thomas Cook Hotel Investments was established in March 2018 to support the growth of Thomas Cook’s own-brand hotels in Spain and Greece. The portfolio of TCHI includes owned hotel properties in Rhodes and Crete under the brand of Sunwing. Thomas Cook Group is one of the world’s leading leisure travel groups, with sales of £9 billion in the year ended 30 September 2017, serving over 20 million customers annually. Thomas Cook was the biggest international tour operator in Greece this year, while it served 3 million customers. Funding of tourism, a vital sector for the Greek economy, is a key priority for Piraeus Bank. With a tourism portfolio in excess of €2 billion, the Bank supports tourism busine

StarLeaf Reinforces Its Global Expansion With New Office in Norway18.10.2018 16:00Tiedote

StarLeaf, a leading provider of premium meeting room solutions and video conferencing services, has expanded its global reach with a new office in Oslo, Norway, enabling it to meet increased demand and serve local customers and partners. This announcement is further testament to the company’s fast-paced growth in key markets, which sees StarLeaf systematically increase its global footprint into key regions and countries. “Norway has a prominent history of originating and using video conferencing and collaboration technologies. However, today businesses are looking for next-generation solutions that deliver greater flexibility and scalability, to match their plans for growth and investment,” said Peter Sanevall, StarLeaf Country Manager for the Nordics Countries. “With the opening of our Oslo office, we are well-positioned to address this demand.” StarLeaf provides an end-to-end business collaboration and meeting room solution delivered by the StarLeaf Cloud and its premium hardware sys

Starbucks Evolves Structure in EMEA to Accelerate Long-Term Strategic Growth18.10.2018 15:30Tiedote

Starbucks Coffee Company (NASDAQ: SBUX) today announced our intention to fully license Starbucks operations in France, the Netherlands, Belgium and Luxemburg to its longstanding strategic partner Alsea, S.A.B. de C.V. (BMV: ALSEA), the largest independent chain restaurant operator in Latin America. Under this proposal, which is subject to relevant local laws, and discussions with relevant employee representatives, Alsea will have the rights to operate and develop Starbucks stores in these markets, building on Starbucks regional growth agenda that drives value through strategic licensed relationships. At the same time the company would introduce a new support structure in its head office in London to better serve an increasingly licensed strategy. “We’re very pleased to build on our 16-year history with Alsea, a long-term strategic partner to Starbucks, with the intention to license our business operations in France, the Netherlands, Belgium and Luxemburg,” said John Culver, group presi

Visa Expands Tokenization Partnership With Netflix to Improve Digital Payments Experience Globally18.10.2018 15:00Tiedote

Building on a pilot program that began in 2017, Visa (NYSE: V) today announced an expansion of Netflix’s use of the Visa Token Service, with a key focus of improving card-not-present authorization rates and enabling a more seamless and secure merchant and customer experience globally. Visa and Netflix are working together to realize the benefit of higher authorization rates resulting from global issuer lifecycle management of Visa tokens. With the Visa Token Service, card details can be replaced with a unique digital identifier used to process payments without exposing the cardholder’s sensitive account information. For those Visa tokens, issuers around the world can push dynamic updates on lost, stolen or expired credentials to enable a frictionless merchant and customer experience. As part of the effort to expand these benefits more broadly to issuers and card-not-present merchants generally, Visa is now working with Netflix and other token participants to measure these improvements

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme